Period pain, it seems, is being treated with the wrong products in the right aisle. A new analysis of supermarket sales and loyalty card records finds that many shoppers reach first for branded period pain tablets, even when identical or more effective options sit within arm’s length at a lower unit dose cost. Researchers compared purchases with clinical guidance on dysmenorrhoea, focusing on non‑steroidal anti‑inflammatory drugs and paracetamol combinations, and saw a persistent tilt toward marketing rather than pharmacology.
The uncomfortable truth is that packaging appears to beat prostaglandin science. Period‑specific brands often contain standard doses of ibuprofen or paracetamol, yet women frequently pay more per milligram than for generic ibuprofen, which targets uterine prostaglandin synthesis and so addresses the mechanism driving cramping. Data from tills show repeat purchases of these branded lines, suggesting habit formation even where analgesic efficacy is not optimal for moderate to severe menstrual pain.
What looks like choice is in practice a quiet penalty on those in pain. Shelf placement, colour cues and gendered labelling steer consumers toward familiar pink boxes, while evidence‑based options, including higher‑dose ibuprofen within recommended limits or combination regimens advised by guidelines, receive less attention. On the bright supermarket shelf, the smallest print carries the biggest difference: the active ingredient line, too often read last.
